
1. j viral hepat. 2017 may;24(5):371-379. doi: 10.1111/jvh.12654. epub 2016 dec 9.

sofosbuvir plus ribavirin treatment-naïve patients chronic hepatitis c
virus genotype 1 3 infection india.

shah sr(1), chowdhury a(2), mehta r(3), kapoor d(4), duseja a(5), koshy a(6),
shukla a(7), sood a(8), madan k(9), sud r(10), nijhawan s(11), pawan r(12),
prasad m(13), kersey k(14), jiang d(14), svarovskaia e(14), doehle b(14), kanwar 
b(14), subramanian m(14), acharya sk(15), sarin s(16).

author information: 
(1)global hospitals, mumbai, maharashtra, india.
(2)institute postgraduate medical education research, kolkata, west
bengal, india.
(3)nirmal hospital pvt ltd, surat, gujarat, india.
(4)global hospitals, hyderabad, andhra pradesh, india.
(5)postgraduate institute medical education research, chandigarh,
chandigarh, india.
(6)lakeshore hospital, kochi, kerala, india.
(7)seth g.s. medical college king edward memorial hospital, mumbai,
maharashtra, india.
(8)dayanand medical college hospital, ludhiana, punjab, india.
(9)artemis hospitals, gurgaon, haryana, india.
(10)medanta - medicity, gurgaon, haryana, india.
(11)sawai man singh medical college hospital, jaipur, rajasthan, india.
(12)fortis memorial research institute, gurgaon, haryana, india.
(13)vgm hospital, coimbatore, tamil nadu, india.
(14)gilead sciences, inc., foster city, ca, usa.
(15)all india institute medical science, new delhi, delhi, india.
(16)institute liver biliary sciences, new delhi, delhi, india.

until 2014, pegylated interferon plus ribavirin recommended standard of
care treatment chronic hepatitis c virus (hcv) infection india.
this open-label phase 3b study, conducted across 14 sites india 31
march 2014 30 november 2015, evaluated efficacy safety sofosbuvir 
plus ribavirin therapy among treatment-naïve patients chronic genotype 1 
3 hcv infection. total 117 patients genotype 1 3 hcv infection 
randomized 1:1 receive sofosbuvir 400 mg weight-based ribavirin (1000 or
1200 mg) daily 16 24 weeks. among genotype 1 infection, the
primary efficacy endpoint sustained virologic response 12 weeks
post-treatment (svr12) reported 90% (95% confidence intervals [ci], 73-98)
and 96% (95% ci, 82-100) patients following 16 24 weeks treatment,
respectively. patients genotype 3 infection, svr12 rates 100% (95% 
ci, 88-100) 93% (95% ci, 78-99) 16 24 weeks therapy,
respectively. adverse events, mild moderate severity,
occurred 69% 57% patients receiving 16 24 weeks treatment,
respectively. common treatment-emergent adverse events asthenia,
headache cough. one patient 24-week group discontinued treatment 
with sofosbuvir study. overall, sofosbuvir plus ribavirin therapy
achieved svr12 rates ≥90% well tolerated among treatment-naïve patients
with chronic genotype 1 3 hcv infection india.

© 2016 john wiley & sons ltd.

doi: 10.1111/jvh.12654 
pmid: 27933698  [indexed medline]

